Observational evidence for buprenorphine's impact on posttraumatic stress symptoms in veterans with chronic pain and opioid use disorder
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD), chronic pain, and substance use disorders are prevalent co-occurring conditions that are challenging to treat individually, and there is no evidence-based treatment for all 3. Buprenorphine, used to treat opioid use disorder and chronic pain, is a partial nociceptin opioid receptor agonist. In preclinical studies, a nociceptin opioid receptor agonist was shown to mitigate PTSD symptoms in acute trauma. We compared buprenorphine to other opioid medications in its impact on PTSD symptoms in patients with chronic pain and opioid and/or other substance use disorders. METHOD: We assembled a retrospective cohort of 382 Iraq and Afghanistan veterans in US Department of Veterans Affairs health care from October 1, 2007, to July 29, 2013, with ICD-9-CM diagnoses of PTSD, chronic pain, and substance use disorders. We used time-varying general estimating equation models to assess the primary outcome, which was change in PTSD symptoms (measured using the PTSD Checklist and the Primary Care PTSD Screen) among veterans initiated on sublingual buprenorphine versus those maintained on moderately high-dose opioid therapy. RESULTS: Twice as many veterans in the buprenorphine group (23.7%) compared to those in the opioid therapy group (11.7%) experienced improvement in PTSD symptoms (P = .001). Compared to veterans in the opioid therapy group, veterans receiving buprenorphine showed significant improvement in PTSD symptoms after 8 months, with increasing improvement up to 24 months (incidence rate ratio = 1.79; 95% CI, 1.16-2.77; P = .009). There were no differences in the longitudinal course of pain ratings between groups. CONCLUSIONS: This observational study is the first to report an incidental effect of buprenorphine compared to opioid therapy in improving PTSD symptoms in veterans.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Buprenorphine use in veterans was associated with a significant improvement in PTSD symptoms after 8 months.
“A recent study on veterans demonstrated that buprenorphine use was associated with a significant improvement in PTSD symptoms after 8 months (63) highlighting overlapping mechanisms between SUD and PTSD.”
From A Biopsychosocial Overview of the Opioid Crisis: Considering Nutrition and Gastrointestinal Health (2019) · cites this paper as [63]
Cited by
Sorted by citations
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Peciña, M., Karp, J. F., Mathew, S. J., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0117-2 · Cited by 188 · see citing works
Maguen, S., Madden, E., Patterson, O. V., DuVall, S. L., Goldstein, L. A., Burkman, K. M., & Shiner, B. R. (2018) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-018-0850-5 · Cited by 64 · see citing works
“Our system can facilitate further research to determine the percentage of veterans that receive minimally adequate EBP for PTSD as well as their level of symptom improvement in a VHA clinic setting outside of a clinical trial using patient reported outcomes stored in the EMR (e.g., Maguen et al.”
BackgroundInfluentialSelf-citationEndogenous Opiates and Behavior: 2016
Bodnar, R. J. (2018) · Peptides · doi:10.1016/j.peptides.2018.01.011 · Cited by 62 · see citing works
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Browne, C. A., Falcón, E., Robinson, S. A., Berton, O., & Lucki, I. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx079 · Cited by 56 · see citing works
“Similarly, a small study noted that the mixed opioid analgesic buprenorphine alleviated PTSD symptomology in patients diagnosed with comorbid chronic pain and PTSD (Seal et al., 2016).”
BackgroundShiner, B. R., Westgate, C. L., Bernardy, N. C., Schnurr, P. P., & Watts, B. V. (2017) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1325033 · Cited by 55 · see citing works
“A limited body of evidence suggests that buprenorphine may also be effective for PTSD symptoms among patients with comorbid pain disorders (Seal et al., 2016).”
BackgroundThe Failing Cascade: Comorbid Post Traumatic- and Opioid Use Disorders.
Elman, I., & Borsook, D. (2019) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.023 · Cited by 40 · see citing works
Posttraumatic stress disorder in opioid agonist therapy: A review.
Ecker, A. H., & Hundt, N. E. (2017) · Psychological Trauma Theory Research Practice and Policy · doi:10.1037/tra0000312 · Cited by 45 · see citing works
A Biopsychosocial Overview of the Opioid Crisis: Considering Nutrition and Gastrointestinal Health
Wiss, D. A. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00193 · Cited by 41 · see citing works
“A recent study on veterans demonstrated that buprenorphine use was associated with a significant improvement in PTSD symptoms after 8 months (63) highlighting overlapping mechanisms between SUD and PTSD.”
BackgroundTorres‐Berrío, A., & Nava-Mesa, M. O. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.08.011 · Cited by 41 · see citing works
Dealing With Complexity and Comorbidity: Comorbid PTSD and Substance Use Disorders
Tripp, J. C., Jones, J. L., Back, S., & Norman, S. B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00176-w · Cited by 36 · see citing works
Shiner, B. R., Westgate, C. L., Simiola, V., Thompson, R., Schnurr, P. P., & Cook, J. M. (2018) · Military Medicine · doi:10.1093/milmed/usy008 · Cited by 28 · see citing works
Shiner, B. R., Westgate, C. L., Gui, J., Maguen, S., Young‐Xu, Y., Schnurr, P. P., & Watts, B. V. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12145 · Cited by 26 · see citing works
Self-citationHser, Y., Zhu, Y., Fei, Z., Mooney, L. J., Evans, E., Kelleghan, A. R., Matthews, A. G., Yoo, C. K., & Saxon, A. J. (2021) · Addiction · doi:10.1111/add.15594 · Cited by 27 · see citing works
“Conflicting findings are probably due, in part, to variation in study designs, most notably differences in the types of mental disorders [e.g. any psychiatric disorder, or one specific mental disorder such as depression, or posttraumatic stress disorder (PTSD)] and in medication treatment (i.e. methadone, buprenorphin…”
BackgroundInfluentialMeshberg‐Cohen, S., MacLean, R. R., Martin, A. M. S., Sofuoglu, M., & Petrakis, I. L. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107026 · Cited by 29 · see citing works
Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder
Meshberg‐Cohen, S., Black, A. C., DeViva, J. C., Petrakis, I. L., & Rosen, M. I. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.010 · Cited by 24 · see citing works
Maguen, S., Holder, N. D., Li, Y., Madden, E., Neylan, T. C., Seal, K. H., Lujan, C., Patterson, O. V., DuVall, S. L., & Shiner, B. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.04.039 · Cited by 23 · see citing works
Self-citationBuprenorphine for the treatment of posttraumatic stress disorder
Lake, E. P., Mitchell, B. G., Shorter, D. I., et al. (2019) · American Journal on Addictions · doi:10.1111/ajad.12860 · Cited by 20 · see citing works
Enman, N. M., Reyes, B. A. S., Shi, Y., Valentino, R. J., & Bockstaele, E. J. V. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.001 · Cited by 18 · see citing works
Buprenorphine: prospective novel therapy for depression and PTSD
Madison, C. A., & Eitan, S. (2020) · Psychological Medicine · doi:10.1017/s0033291720000525 · Cited by 19 · see citing works
Upadhyay, J., Verrico, C. D., Cay, M., Kodele, S., Yammine, L., Koob, G. F., & Schreiber, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00008-0 · Cited by 17 · see citing works
Did the War on Terror Ignite an Opioid Epidemic?
Cesur, R., Sabia, J. J., & Bradford, W. D. (2019) · National Bureau of Economic Research · doi:10.3386/w26264 · Cited by 10 · see citing works
“Post-Traumatic Stress Disorder, a condition with which nearly one-fifth of active-duty servicemembers have been diagnosed (Tanielian and Jaycox 2008; Sabia and Skimmyhorn 2019), is associated with increased risk of opioid addiction (Seal et al. 2016; Shiner et al. 2017; Meier et al. 2014).”
BackgroundPosttraumatic Stress Disorder and Substance Use Disorder Screening, Assessment, and Treatment
Patton, S. C., Watkins, L. E., Killeen, T. K., & Hien, D. A. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01547-8 · Cited by 10 · see citing works
“There have also been some preliminary reports that buprenorphine /naltrexone may have a favorable impact on PTSD symptom severity through its partial opioid kappa receptor antagonism action [72, 73].”
Riblet, N. B. V., Gottlieb, D. J., Shiner, B. R., Cornelius, S. L., & Watts, B. V. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1701218 · Cited by 10 · see citing works
“Although there is some evidence that patients with PTSD and substance use disorder may also experience significant improvements in PTSD symptoms with MAT (Seal et al., 2016), we were unable to directly compare our findings with this evidence because our study focused solely on mortality.”
BackgroundResultElman, I., Upadhyay, J., Lowen, S. B., Karunakaran, K. D., Albanese, M. A., & Borsook, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604867 · Cited by 11 · see citing works
Theranostic pharmacology in PTSD: Neurobiology and timing
Koek, R. J., & Luong, T. N. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.001 · Cited by 10 · see citing works
Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia
Maraschin, J. C., Frias, A. T., Hernandes, P. M., Batistela, M. F., Martinez, L. M., Joca, S. R. L., Graeff, F. G., Audi, E. A., de Andrade, T. G. C. S., & Zangrossi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113651 · Cited by 8 · see citing works
Shiner, B. R., Gui, J., Westgate, C. L., Schnurr, P. P., Watts, B. V., Cornelius, S. L., & Maguen, S. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13158 · Cited by 8 · see citing works
Self-citationDeath Ambivalence and Treatment Seeking: Suicidality in Opiate Addiction
Conroy, S. C., & Bjork, J. M. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0152-2 · Cited by 7 · see citing works
Pharmacological treatments for co-occurring PTSD and substance use disorders: A systematic review
Swannell, M., Bradlow, R. C. J., Pham, D., Gabriel, J., Manahan, Y., & Arunogiri, S. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209601 · Cited by 7 · see citing works
Petrakis, I. L., Meshberg‐Cohen, S., Nich, C., Kelly, M. M., Claudio, T., Jane, J. S., Pisani, E., & Ralevski, E. (2024) · American Journal on Addictions · doi:10.1111/ajad.13557 · Cited by 5 · see citing works
Alexander‐Bloch, A. F., Raznahan, A., Shinohara, R. T., Mathias, S. R., Bathulapalli, H., Bhalla, I. P., Goulet, J. L., Satterthwaite, T. D., Bassett, D. S., Glahn, D. C., et al. (2020) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2019.0790 · Cited by 5 · see citing works
“There are encouraging trends in this direction, including the investigation of psychotherapeutic strategies for co-morbid PTSD and substance use disorder [72], as well as pharmacological interventions [73] and interventions at the level of healthcare systems [74].”
BackgroundDavis, L. L., Petrakis, I. L., Pilkinton, P. D., Nolen, T. L., Vandergrift, N., Hirsch, S. C., Norrholm, S. D., & Kosten, T. R. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15155 · Cited by 5 · see citing works
Meshberg‐Cohen, S., Cook, J. M., Bin-Mahfouz, A., & Petrakis, I. L. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107475 · Cited by 5 · see citing works
Predictors of PTSD Treatment Retention and Response: A Systematic Review
Maglione, M., Chen, C., Franco, M., Gizaw, M., Shahidinia, N., Baxi, S. M., & Hempel, S. (2022) · RAND Corporation eBooks · doi:10.7249/rr4191 · Cited by 4 · see citing works
Grinchii, D., Lacinová, Ľ., & Dremencov, E. (2023) · General Physiology and Biophysics · doi:10.4149/gpb_2023010 · Cited by 3 · see citing works
The effect of combat deployments on veteran opioid abuse
Cesur, R., Sabia, J. J., & Bradford, W. D. (2024) · Health Economics · doi:10.1002/hec.4812 · Cited by 2 · see citing works
Other Psychiatric Disorders, Psychosocial Factors, Sleep, and Pain
Bair, M. J., & Owen‐Smith, A. A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197675250.003.0006 · Cited by 3 · see citing works
Mei, X., Wu, H., Yuan, T., Samsom, J., Ying, S., Liu, X., Xu, T., Liu, F., & Shen, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03538-y · Cited by 1 · see citing works
“Similarly, another retrospective study demonstrated that veterans receiving bupre-norphine showed signi fi cant improvement in PTSD symptoms after 8 months, with increasing improvement up to 24 months [88].”
Pain and Addiction in Military Personnel and Veterans
Robeck, I. R., Hunt, S. C., Burgo-Black, L., McKelvey, J., Siddiqui, A., & Mariano, A. J. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190265366.003.0033
Pain and Addiction in Patients with Post-Traumatic Stress Disorder
Eraker, S. A. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190265366.003.0025
Medical Treatment of Pain in Chronic Pancreatitis
Drewes, A. M., Kuhlmann, L., Andresen, T., & Olesen, S. S. (2021) · doi:10.1002/9781119570097.ch36
Pain, Addiction, and Suicidality Among Veterans
Banou, E., Angeli, N., Sandusky, S., & Miller, S. N. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197646588.003.0013
Evaluating the Impact of Buprenorphine on Depressive Symptoms Among Veterans with Chronic Pain
Cetto, A. V., Chandler, M. W., Shah, N. K., Luciani, L. L., & Painter, J. T. (2024) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2024.2427877
“Seal, et al. found buprenorphine significantly improved PTSD symptoms in Veterans with chronic pain and substance use disorder (19).”
Buprenorphine as a unique opioid analgesic – an overview ofexperimental and clinical data
Dębowska, P., Przeklasa-Muszyńska, A., & Kocot-Kępska, M. (2024) · Ból · doi:10.5604/01.3001.0054.7779
- Authors
- Seal, K. H., Maguen, S., Bertenthal, D., Batki, S. L., Striebel, J., Stein, M. B., Madden, E., & Neylan, T. C.
- Affiliations
- San Francisco VA Medical Center (US)
- University of California San Diego (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-03-01
- Volume
- 77
- Issue
- 09
- Pages
- 1182-1188
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2415939497
- Cited by
- 44
- References
- 0
- Citations by year
- 2026: 1 · 2024: 8 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 7 · 2018: 12 · 2017: 3
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Keywords
- buprenorphine, post-traumatic stress disorder, chronic pain, opioid use disorder, veterans, opioid therapy, Iraq and Afghanistan veterans, comorbid substance use disorders
- MeSH terms
- Nociceptin, Adult, Buprenorphine, Female, Humans, Male, Narcotic Antagonists, Opioid-Related Disorders, Receptors, Opioid, Retrospective Studies, Stress Disorders, Post-Traumatic, United States, Veterans, Comorbidity, Outcome Assessment, Health Care, Opioid Peptides, Iraq War, 2003-2011, Afghan Campaign 2001-, Opiate Substitution Treatment, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
